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Abstract
Background: Blood pressure (BP) lowering in people who have had a stroke or transient ischaemic attack (TIA)
leads to reduced risk of further stroke. However, it is not clear what the target BP should be, since intensification of
therapy may lead to additional adverse effects. PAST BP will determine whether more intensive BP targets can be
achieved in a primary care setting, and whether more intensive therapy is associated with adverse effects on
quality of life.
Methods/Design: This is a randomised controlled trial (RCT) in patients with a past history of stroke or TIA.
Patients will be randomised to two groups and will either have their blood pressure (BP) lowered intensively to a
target of 130 mmHg systolic, (or by 10 mmHg if the baseline systolic pressure is between 125 and 140 mmHg)
compared to a standard group where the BP will be reduced to a target of 140 mmHg systolic. Patients will be
managed by their practice at 1-3 month intervals depending on level of BP and followed-up by the research team
at six monthly intervals for 12 months.
610 patients will be recruited from approximately 50 general practices. The following exclusion criteria will be
applied: systolic BP <125 mmHg at baseline, 3 or more anti-hypertensive agents, orthostatic hypotension, diabetes
mellitus with microalbuminuria or other condition requiring a lower treatment target or terminal illness.
The primary outcome will be change in systolic BP over twelve months. Secondary outcomes include quality of
life, adverse events and cardiovascular events.
In-depth interviews with 30 patients and 20 health care practitioners will be undertaken to investigate patient and
healthcare professionals understanding and views of BP management.
Discussion: The results of this trial will inform whether intensive blood pressure targets can be achieved in people
who have had a stroke or TIA in primary care, and help determine whether or not further research is required
before recommending such targets for this population.
Trial Registration: ISRCTN29062286
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Background
Stroke is the third largest cause of death in England, and
the single largest cause of adult disability[1]. A National
Audit Office report (2005) highlighted the high cost of
stroke to the NHS: about £2.8 billion per year in direct
care costs, and an additional £1.8 billion per year cost to
the wider economy due to lost productivity and disabil-
ity [2]. Recent estimates suggest that between 30-45% of
strokes are recurrent events, [3] so more effective sec-
ondary prevention could result in significant savings: the
National Audit Office estimates that preventing just 2%
of strokes in England in a year could save care costs of
over £37 million [2]. NICE has identified better control
of hypertension as one of the interventions that are cost
saving for the NHS [4].
The PROGRESS trial demonstrated that blood pres-
sure lowering is beneficial in reducing risk of stroke
amongst both hypertensive and non-hypertensive indivi-
duals with a history of stroke or TIA recruited in sec-
ondary care immediately after their cerebrovascular
event. In this trial, patients were randomised to either a
combination of an ACE inhibitor and thiazide diuretic
against double placebo, or an ACE inhibitor alone
against single placebo. The decision to randomise to
one or two agents was made by the supervising physi-
cian on the basis of whether or not they thought it was
safe to randomise an individual patient to two agents.
Mean blood pressure in the intervention arm was
reduced from 147 mmHg systolic by 9 mmHg (SE 0.3),
and this was associated with a 28% reduction in stroke
risk [5]. The positive result of the PROGRESS trial
raises a supplementary question: by how much should
blood pressure be lowered? No randomised trials have
specifically compared different target blood pressures
(BP) in the post-stroke/TIA population. Observational
data (although not collected specifically in people with a
history of stroke or TIA) suggest that the lower the
blood pressure, the lower the risk of vascular mortality,
at least down to 115 mmHg systolic [6,7]. There is
some evidence from PROGRESS to support this, in that
the sub-group of patients whose baseline BP was
between 120 and 140 mmHg who were randomised to
combination therapy had a significantly reduced risk of
stroke compared with control, though this benefit was
not observed in patients who were randomised to a sin-
gle agent [8]. Guidelines have tended to interpret this
evidence by recommending a target of 130 mmHg for
systolic blood pressure in people with cerebrovascular
disease [9,10]. However, the question remains whether
such a target is prudent in general (42% were rando-
mised to a single agent and gained no benefit) and
whether it is achievable in primary care (PROGRESS
was secondary care based) [5].
Long term management of blood pressure following
stroke and TIA is predominantly carried out in primary
care. Recent studies of blood pressure control in this
setting paint a mixed picture of implementation of
guidelines. In a study of seven general practices in
South Birmingham in 2002, 63% of patients with a pre-
vious stroke or TIA had BP above the 140 mmHg tar-
get, and 80% above the 130 mmHg target [11]. 68% of
these patients were prescribed BP lowering therapy. An
analysis of general practice data on the QRESEARCH
database for 2002-2004 found that of all patients with
incident stroke, blood pressure was not recorded in 25%
of patients, and where it was recorded, it was above the
140 mmHg target in 47% [12]. An analysis of the impact
of the Quality Outcomes Framework (QOF) carried out
for the National Audit Office found that the proportion
of people with a history of stroke or TIA who had their
BP measured in the preceding 15 months rose from
89% to 95% between 2004 and 2005, and the proportion
with a BP below 150 mmHg (the target level for the
QOF) rose from 69% to 80% suggesting some improve-
ment [13]. An analysis of the care of over three thou-
sand patients who had a TIA during 2004-5 found that
60% had a BP equal to or below the 140 mmHg target,
though only 50% were on any blood pressure lowering
therapy [14].
In summary, although there is some evidence that
blood pressure lowering in people who have had a
stroke or TIA is beneficial, there is no clear guidance on
what the target BP should be. Furthermore, data col-
lected from primary care suggest that guidelines from
the British Hypertension Society and Intercollegiate
Stroke Working Party are not being fully implemented.
This research is designed to support implementation of
the guidelines by both addressing the gaps in the under-
lying evidence base, and testing a specific mechanism
for implementation of blood pressure lowering.
Methods/Design
Study aims
The primary aim of Past BP is to determine whether a
more intensive target BP for people with stroke or TIA in
a pragmatic primary care setting will lead to a lower BP.
Secondary aims of the research are to:
• determine the impact of a more intensive BP target
on patient quality of life;
• identify the barriers to implementation of more
intensive blood pressure lowering;
• to explore whether the potential benefits associated
with intensive blood pressure lowering might be out-
weighed by potential adverse effects on quality of life
and costs.
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The latter point will be explored by economic model-
ling. If there is uncertainty as to whether there is net
benefit from intensive blood pressure lowering, then
there would be a case for a trial of different targets for
BP lowering in primary care that is powered to detect
differences in clinical end-points.
The study will also investigate patients’ understanding
and beliefs about the relationship between blood pres-
sure and stroke, and patients and healthcare profes-
sionals experience of participating in the study, which
may contribute to the success or otherwise of the
intervention.
Study design and setting
Past BP is a primary care based pragmatic randomised
controlled trial (RCT) in which people with stroke or
TIA are randomised to an intensive blood pressure (BP)
target group (target 130 mmHg systolic, or 10 mmHg
reduction in systolic BP if baseline BP 125 - 140
mmHg) or a standard BP target group (target 140
mmHg systolic).
We will also use qualitative methodologies to investi-
gate patient and healthcare professionals understanding
and views of BP management. Grounded theory meth-
ods will guide sampling, data collection and data analy-
sis [15,16]. Sampling will be done purposively to allow
for the maximum variety of characteristics. Semi-struc-
tured interviews will be carried out [17] and will con-
tinue until new concepts are no longer being generated
and theoretical saturation is reached.
Ethical Considerations
Full ethical approval for this study has been obtained
from Warwickshire Research Ethics Committee, refer-
ence 08/H1211/121. A Data Monitoring Committee and
a Trial Steering Committee will monitor the progress of
the RCT.
Randomised controlled trial
Study Interventions
Management of both treatment groups will follow study
specific treatment protocols that reflect the current
NICE guidelines [18]. However, the thresholds for inter-
vention between the two treatment groups are different:
all patients in the intensive target arm will have their BP
lowering therapy intensified at trial entry since the tar-
get will be automatically below their baseline BP
whereas only those patients in the standard arm whose
BP is above 140/90 mmHg will have their therapy inten-
sified at the outset.
Identification of eligible patients
Eligible patients will be identified from general practices
from the Central England Primary Care Research Net-
work and from the Midlands Research Practice Consor-
tium (MidReC). Each practice will run a search of their
clinical computer system to identify all patients on the
stroke/TIA register. Where possible, the computer
search will exclude patients with clear exclusion criteria
(see table 1). The GP will also remove patients for
whom a study invitation would be inappropriate (for
example, those with a terminal illness). Patients with no
clear exclusion criteria at this stage will be sent a letter
inviting them to attend a study baseline clinic
appointment.
Baseline clinic appointment
This clinic appointment is carried out by a Research
Nurse. At this appointment the nurse will: confirm the
stroke/TIA diagnosis through review of medical records
and patient interview; determine whether there are any
exclusion criteria present; and collect baseline data (see
table 2). If the patient is eligible and willing to take part,
the nurse will also gain written informed consent prior
to randomisation, and will telephone the randomisation
service to obtain treatment group allocation.
Once the treatment allocation has been obtained,
patients in the intensive target group and any patients
who have been randomised to the standard treatment
group whose BP is above the target of 140 mmHg will
see a GP in order to have their treatment intensified
using the study specific treatment protocol (see figure 1).
Patients in the standard group whose BP is below target
will receive an appointment to see the practice nurse
three months post randomisation.
Randomisation
The randomisation will use minimisation to balance the
randomised groups on the basis of age (<80, ≥80), sex,
diabetes mellitus, atrial fibrillation (because of the diffi-
culties of obtaining accurate BP measurements in this
group), baseline systolic BP and practice.
Patient follow-up procedures
Patients will be followed up from trial entry for 12
months. Follow up will be carried out in several ways.
Firstly, practice nurses (PNs) will see patients at 1-3
monthly intervals, depending on BP and treatment allo-
cation. (see figure 2) The PN will take a patient’s BP and
refer them to the GP if the BP is above target, or if the
patient is having problems with adverse effects to their
BP medication. The GP will then adjust the medication,
following the study treatment protocol (see figures 1). At
6 and 12 months patients will be followed up by a
research nurse (RN) where details of primary and sec-
ondary outcomes will be collected. (see table 2). Finally,
the records of patients will be flagged at the NHS Central
Register.
Patient outcome measures
The primary outcome measure is a change in systolic
blood pressure between baseline and 12 months. Blood
pressure measurements are performed in a standardised
way, using BHS validated automated electronic monitors
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Table 1 Study inclusion and exclusion criteria
Inclusion criteria
On practice TIA/stroke register
Exclusion criteria
Systolic BP < 125 mmHg at baseline;
Already taking 3 or more anti-hypertensive agents; orthostatic hypotension (>20 mmHg postural change in systolic BP after 1 minute standing)
Patient already has a treatment target of 130 mmHg systolic BP specified
Unable to provide informed consent.
Insufficient corroborative evidence of stroke/TIA from medical record and patient interview
Table 2 Timing and content of study assessments
Baseline data: research nurse administered
Socio-demographic characteristics:
Age; Ethnicity; Gender; Postcode
Validation of stroke/transient ischaemic attack:
Review of medical records with patient history
Clinical measures:
Six blood pressure (BP) measurements, calculating mean of 2nd and 3rd measurements and recording details of: arm used; arm circumference;
BP cuff size; and time BP measurement started
24 hour ambulatory BP recording
Medical history
Previous history of angina, myocardial infarction, heart failure, atrial fibrillation, CABG/angioplasty (balloon)/or stent, peripheral vascular disease,
diabetes, chronic kidney disease. Current prescription medications. Smoking status and alcohol intake
Patient questionnaires - self-completion
Health related quality of life assessed by the SF-36 [20] and EQ-5 D [19]
Disability assessed by the Modified Rankin Scale [26]
Medication Adherence Report Schedule (MARS) for BP treatment [27]
Symptoms/side effects questionnaire
Patient questionnaire - research nurse completion
Cognitive function assessed by the Mini Mental State [21]
Eligibility and consent
Review inclusion and exclusion criteria and record outcome of consent process
Patient follow up for BP control
GP appointment at any time patient BP medication review required
Action taken to treat/monitor side effects
Action taken to treat BP above target using study algorithm (see figure 1)
Make appointment with practice nurse at appropriate interval (see figure 2)
Practice nurse follow up - 1-3 month intervals
Six BP readings, as per baseline data collection
Side effects of BP medication
Refer patient to GP or make further appointment with practice nurse (see figure 2)
Patient follow up by research team
Research nurse follow up - 6 and 12 months post randomisation
Six BP readings, as per baseline data collection
24 hour ambulatory BP recording (12 month f/u only)
Check details of patient visits to GP and practice nurse
Diagnosis of key medical conditions (as per baseline data collection) since baseline or the previous research nurse follow up
All hospital admissions or outpatient visits since baseline or the previous research nurse follow up
Record of medications introduced since baseline or the previous research nurse follow up
Monitor compliance with repeat medication since baseline or previous research nurse follow up
Completion of patient questionnaires, as per baseline data collection.
Obtaining information on patients who died
Records flagged at NHS central register
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supplied and validated for the study. The patient will be
seated for 5 minutes and then 6 measurements will be
taken at minute intervals. The second and third mea-
surements are averaged to give the reading. As the
intensive target group have their BP monitored more
frequently than those in the standard group, there may
be some diminution of the ‘white coat’ effect in this
group; the mean of readings 2 to 6 and the mean of 5
and 6 will be used to monitor for this. Any differences
between the groups in the primary outcome should be
sustained in the mean of the 5th and 6th readings (by
which time any accommodation effect is likely to have
worn off), enabling us to determine whether accommo-
dation has a significant effect in this study. 24 hour
blood pressure recordings using an ambulatory sphyg-
momanometer will be recorded at baseline and at twelve
months. 24 hour ambulatory measurement will be unaf-
fected by accommodation, so will provide further evi-
dence as to whether or not this was significant in this
study.
A variety of secondary outcome measures are also
assessed during the RN follow up appointments. (see
table 2) Key secondary outcomes are: additional
measures of BP (change in diastolic and mean daytime
ambulatory systolic BP between baseline and twelve
months); measures of adherence (including GP adher-
ence to protocol and patient adherence to prescribed
medication); quality of life (EQ5 D [19]; SF36 [20]); side
effects, tolerability and adverse events; clinical outcomes
(including major cardiovascular events [composite of
fatal and non-fatal stroke, myocardial infarction or fatal
coronary heart disease and other cardiovascular death],
all cause mortality, cognitive function [21] and hospital
admissions). Key secondary events (stroke; myocardial
infarction; fatal coronary heart disease and other cardio-
vascular death) will be reviewed by independent clini-
cians blinded to treatment to ensure unbiased coding of
these events.
Sample size
Randomisation of 610 patients (305 per arm), with 12
months of follow-up, will detect a 5 mmHg difference in
systolic BP between groups with 90% power and at a
significance level of 5% assuming a standard deviation of
17.5 mmHg (a conservative estimate of standard devia-
tion falling between 16, a figure derived from the same
sort of patients as included in this study [11] and 19,
Figure 1 Summary of Algorithm for BP control.
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the standard deviation in the PROGRESS Study [5]).
The calculation assumes that: a 5 mmHg difference in
systolic BP is of clinical significance, leading to a 20%
reduction in major vascular events;[22] that there will
be 5% mortality at six months, and a further 10% of
patients will not have their BP measured at six months.
With regard to ambulatory blood pressure measure-
ment, one of the secondary outcomes of the study, ran-
domisation of 450 patients (225 per arm) will detect a
4 mmHg difference in systolic BP between groups with
90% power and at a significance level of 5% assuming a
standard deviation of 11.7 mmHg [23]. This calculation
assumes that 80% of patients will have ambulatory
blood pressure measured at 12 months.
To recruit patients from primary care, an estimate of
the number of practices is required. Approximately 50
practices with an average list size of 7,500 will be
needed in order to recruit the required number of
patients. This will generate 5,625 patients on practice
TIA/stroke registers (from the QOF data, the overall
prevalence of TIA/stroke in primary care is 1.5%). From
our analysis of South Birmingham data [11], we antici-
pate that 13% of these patients will be ineligible because
they are already on three or more anti-hypertensives,
and 28% because they will not fulfil the diagnostic cri-
teria for a history of stroke or TIA for the study [24].
We assume that 30% of patients will respond to the
invitation to attend a study clinic, that 24% of them will
be ineligible due to a systolic BP below 125, and a
further 15% will decline to take part after discussion
with the research nurse. This equates to the recruitment
of 12 patients per practice with an average list size of
7,500.
Statistical analysis
The principal analyses will use generalised linear mod-
els, accounting for baseline BP as a patient level covari-
ate, and practices as random effects and compare
differences in systolic BP (primary outcome), and differ-
ences in diastolic BP, quality of life, adherence and fre-
quency of adverse effects (secondary outcomes). We will
look at effect on systolic BP lowering in pre-specified
sub-groups: diabetes; atrial fibrillation; and age group.
Clinical event rates will be monitored by treatment allo-
cation by the Data Monitoring & Ethics Committee, but
only aggregated rates will be made available to the
investigators.
Economic evaluation
Decision analytical modelling will be undertaken to
synthesise data from the trial and the literature in order
to determine whether potential benefits of intensive
blood pressure lowering (by lowering the risk of stroke)
are outweighed by potential adverse effects on quality of
life. Ultimately the model analyses will inform whether a
further trial, powered to detect differences in clinical
end-points, is required.
A Markov model will be constructed to consider
intensive target and standard target strategies for blood
pressure lowering in patients with a history of stroke or
TIA. The clinical events of importance in the model are
further stroke events, myocardial infarction (MI) and
other cardiovascular related mortality. Data from the
trial and literature will inform the probability of these
events occurring and the risk reduction afforded by the
alternative strategies. Attached to each health state will
be associated health state utility values (quality of life)
in order that quality-adjusted life years (QALYs) can be
calculated. Quality of life on each treatment strategy will
be obtained from the trial data on EQ-5 D, and previous
studies will inform post-stroke and post-MI values. In
addition, in order that cost-effectiveness analyses can be
Figure 2 follow up procedure.
Fletcher et al. BMC Cardiovascular Disorders 2010, 10:37
http://www.biomedcentral.com/1471-2261/10/37
Page 6 of 8
undertaken, the model will be populated with costs of
the therapies prescribed in each strategy and acute and
long term costs of further cardiovascular events.
In order to explore uncertainties in the analyses,
deterministic sensitivity analysis is proposed to test the
robustness of the model when varying key model para-
meters and structural assumptions. Probabilistic sensitiv-
ity analysis will be undertaken to incorporate the
uncertainty around parameter values and quantify the
overall decision uncertainty, and inform whether further
research is required.
Qualitative Study
Sampling
A purposively selected sample of 30 patients (10 each
from intervention and control and 10 patients who
declined the invitation to participate), and 20 healthcare
professionals (Health Care Assistants (HCAs), nurses
and GPs) will be selected for interview.
Patient Sampling Strategy Sampling will be carried out
on the basis of study arm (intervention or control), with
a further group of people who did not consent to parti-
cipate in the trial also being invited to attend for an
interview. Within each group, participants will be
selected on the basis of: age (tertiles); socio-economic
status (using IMD scores); number of different classes of
medications; and whether they have had a stroke or a
TIA. A researcher will randomly select patients from
these categories, ensuring that similar numbers of
patients in all categories are included.
Health care professionals sampling strategy Practices
participating in the study were selected to ensure a
range of practice characteristics are represented, includ-
ing practice size and socio-economic status. A
researcher will randomly select 20 practitioners from
these practices and send an invitation letter and infor-
mation sheet, inviting them to take part in an interview.
Patients and practitioners who fail to respond to invi-
tation or who do not wish to participate will be replaced
by another patient/practitioner with similar characteris-
tics. This process will continue until theoretical satura-
tion is achieved and interviews cease.
Interviews
Semi-structured, face-to-face, in-depth interviews will be
carried out in patients’ own homes or in other suitable
locations, or with healthcare professionals in the sur-
gery, and will be conducted by a researcher trained in
qualitative interviewing techniques. Fully informed con-
sent will be obtained from interviewees at the start of
the interview, and a consent form signed. An interview
topic guide will be used (see additional file 1) which will
then be modified and refined during the first interviews.
Each interview is expected to last between 60 and 90
minutes, and will be audio taped and transcribed
verbatim.
Data Analysis
Data collection and analysis will be iterative, occurring
as data collection in the interviews proceeds. Data will
be analysed using a thematic approach, based on the
principles of ‘Framework’ analysis [25] and using Frame-
work software. The research team will actively contri-
bute to the development of the analysis and conceptual
framework and their different disciplinary and profes-
sional backgrounds will maximise theoretical sensitivity
[16].
Time plan
Patient recruitment began in July 2009 and is planned to
continue until February 2011. By October 2009, 23
patients (4% of target) have been recruited into the trial.
Interviews will commence in January 2010 and are
expected to be completed by February 2011.
Discussion
The results of this trial and the health economic analysis
will provide insight into the role of intensive blood pres-
sure targets for people who have had a stroke or TIA. If
the trial is negative and a significant difference in systo-
lic blood pressure is not observed between the two
study arms, then the embedded qualitative work will be
of importance to determine why low blood pressure tar-
gets did not lead to lower blood pressure. If the trial is
positive, then the critical question remains as to whether
striving for lower blood pressure targets is appropriate.
If we observe no difference in adverse event rates or
quality of life between the two arms of the trial, then it
is likely that aiming for lower blood pressure targets will
be worthwhile, given the benefits of reduced stroke risk
that were observed in the PROGRESS trial [5]. This will
be tested by our economic analysis. If, on the other
hand, the lower blood pressures are at the cost of higher
adverse event rates, then it may be that a further trial
powered to detect differences in clinical end-points will
be required to guide clinical practice.
Additional material
Additional file 1: Interview guides. This file contains a copy of the
interview guides for Patients and Health Care Professionals.
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